No Magic Shield 🛡️: What Dementia Prevention Really Promises 🧠
Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!
🧠 Can dementia be avoided? A thoughtful Nature feature reminds us: lifestyle matters, but it is not a magic shield. Physical activity, social engagement, vascular risk control, hearing and vision care, and healthier environments may reduce risk — yet trials show modest cognitive benefits and no guaranteed prevention. The key message for clinicians: advise brain-healthy habits honestly, without blame. Prevention is personal, vascular, sensory, and societal. 🌍✨ #Dementia #Alzheimers #BrainHealth #HealthyAging #Prevention #MedicalPodcasts
info_outline
The ICU Feeding Paradox: When More Is Not Better ⚖️🥗
Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!
🥄 In ICU nutrition, more is not always better. This NEJM review highlights a phase-specific approach: begin enteral nutrition early when feasible, use restrictive energy delivery during acute catabolism, avoid routine high-dose protein—especially in acute kidney injury—and advance feeding gradually as physiology recovers. 🧬💪 Prevention of refeeding syndrome, glucose control, and careful bedside monitoring remain essential. Precision nutrition may be the next frontier in critical care. 🎯 #CriticalCare #Nutrition #MedicalPodcasts
info_outline
The Future of Aging Is Organ-Specific 🧠
Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!
🧬 We may all share a birthday, but our organs do not age at the same pace. This insightful Nature Medicine review examines epigenetic, proteomic, cellular, imaging, and artificial intelligence–based aging clocks—and their potential to predict disease, guide prevention, and assess whether aging can be modified.
info_outline
Inflammaging Decoded: Measuring the Aging Immune System 🔥
Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!
🧬 New Nature Medicine review reframes immune aging as a clinical-trial target, not just a biologic curiosity. The authors propose five criteria for immune-aging biomarkers: immune relevance, temporal association, internal validity, predictive value, and responsiveness. Key message: move beyond single markers like CRP or IL-6 toward multidimensional, dynamic, standardized measures such as iAge, IMM-AGE, and functional immune-response assays. The future endpoint may be immune resilience. 🛡️ #Geroscience #Healthspan #Immunology #Biomarkers #MedicalPodcasts
info_outline
Fibrosis, Abstinence, Transplant 🩺: The New Clinical Map of Alcohol Related Liver Disease
Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!
🍷 Alcohol-related liver disease is no longer a “late-stage liver clinic” problem—it is a primary care, cardiometabolic, addiction medicine, and transplant challenge. This JAMA Review highlights rising mortality, underdiagnosis, modern tools such as AUDIT, PEth, FIB-4, VCTE, and ELF testing, and the central therapeutic truth: sustained abstinence changes prognosis. Early fibrosis detection may also motivate behavior change. A must-read for clinicians caring for patients where alcohol, obesity, diabetes, and liver risk intersect. 🩺🔍 #LiverDisease #ALD #MedicalPodcasts #Hepatology
info_outline
Soranus of Ephesus: The Physician Who Elevated Women’s Health 🌿👩⚕️
Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!
⚕️ Soranus of Ephesus (c. 98–138 CE) stands among the most important physicians of the ancient world—especially for women’s health. A leading representative of the Methodic school, he practiced in Alexandria and Rome, wrote with unusual clarity, and left a lasting mark through his great treatise on gynecology and midwifery. His work addressed pregnancy, childbirth, newborn care, bandaging, fractures, and acute and chronic disease with a practical, disciplined voice. 👶📚 What makes Soranus especially striking is his balance: method without rigidity, scholarship without vanity,...
info_outline
Fatty Liver, Fiercer Metastases, Future Targets 🧬
Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!
🧬 New Nature study: fatty liver may do more than coexist with colorectal cancer liver metastases — it may shape their biology. Steatotic livers were linked to more aggressive “replacement” metastases, driven by fatty acid oxidation, MYC stabilization, proline synthesis, and collagen remodeling. The practical pearl: liver-fat content may become a biomarker for prognosis and trial selection, especially for MYC-targeted therapy. Metabolism is not background noise — it may be the soil that scripts metastatic fate. 🎯
info_outline
🩸 The Dementia Signal in Blood: GDF15 Points to Vascular Risk
Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!
🧠 New Science Advances study: plasma growth/differentiation factor-15 (GDF15) measured in midlife and late life predicted long-term dementia risk, with the strongest signal for vascular dementia. The study links GDF15 to cerebral small vessel disease, neurodegeneration, phosphorylated tau, and neuroimmune activation—suggesting this blood biomarker may be more than a bystander. 🩸🔬 Key clinical pearl: dementia prevention may need to look beyond amyloid and focus earlier on vascular–immune biology. #Dementia #GDF15 #Neuroinflammation #VascularDementia #MedicalPodcasts
info_outline
🇺🇸 When Physicians Signed History ✍️
Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!
🩺 In 1776, physicians were not just healers—they were signers, soldiers, governors, judges, and architects of a new republic. This NEJM Perspective reminds us that 5 Declaration signers were doctors, and asks a timely question: as health policy now shapes vaccines, research, insurance, and public trust, have physicians become too distant from national leadership? 🇺🇸 From bedside to body politic, the call for civic engagement still echoes. #MedicalHistory #PhysicianLeadership #HealthPolicy #NEJM #MedicalPodcasts
info_outline
Antiplatelets After ASCVD: Less Autopilot, More Judgment 🧭
Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!
🩸 Antiplatelet therapy is no longer “aspirin for all” or “DAPT by habit.” The 2026 ACC Scientific Statement reframes care around precision: ischemic risk, bleeding risk, PCI/ACS context, PAD or stroke phenotype, surgery, anticoagulation, and adherence. The modern message: choose the right agent, right intensity, and right duration—then reassess. Platelets may be small, but the decisions are not. ⚖️🔬 Source: 2026 ACC Scientific Statement on antiplatelet therapy.
info_outlineCoronary CT angiography-guided management of patients
with stable chest pain: 10-year outcomes from the SCOT-
HEART randomised controlled trial in Scotland
Michelle C Williams, Ryan Wereski, Christopher Tuck, Philip D Adamson, Anoop S V Shah, Edwin J R van Beek, Giles Roditi, Colin Berry,Nicholas Boon, Marcus Flather, Steff Lewis, John Norrie, Adam D Timmis, Nicholas L Mills, Marc R Dweck, David E Newby, on behalf of theSCOT-HEART Investigators*
Summary
Background The Scottish Computed Tomography of the Heart (SCOT-HEART) trial demonstrated that management
guided by coronary CT angiography (CCTA) improved the diagnosis, management, and outcome of patients with
stable chest pain. We aimed to assess whether CCTA-guided care results in sustained long-term improvements in
management and outcomes.
Methods SCOT-HEART was an open-label, multicentre, parallel group trial for which patients were recruited from
12 outpatient cardiology chest pain clinics across Scotland. Eligible patients were aged 18–75 years with symptoms of
suspected stable angina due to coronary heart disease. Patients were randomly assigned (1:1) to standard of care plus
CCTA or standard of care alone. In this prespecified 10-year analysis, prescribing data, coronary procedural
interventions, and clinical outcomes were obtained through record linkage from national registries. The primary
outcome was coronary heart disease death or non-fatal myocardial infarction on an intention-to-treat basis. This trial
is registered at ClinicalTrials.gov (NCT01149590) and is complete.
Findings Between Nov 18, 2010, and Sept 24, 2014, 4146 patients were recruited (mean age 57 years [SD 10], 2325 [56·1%] male, 1821 [43·9%] female), with 2073 randomly assigned to standard care and CCTA and 2073 to standard care
alone. After a median of 10·0 years (IQR 9·3–11·0), coronary heart disease death or non-fatal myocardial infarction
was less frequent in the CCTA group compared with the standard care group (137 [6·6%] vs 171 [8·2%]; hazard ratio
[HR] 0·79 [95% CI 0·63–0·99], p=0·044). Rates of all-cause, cardiovascular, and coronary heart disease death, and
non-fatal stroke, were similar between the groups (p>0·05 for all), but non-fatal myocardial infarctions (90 [4·3%] vs
124 [6·0%]; HR 0·72 [0·55–0·94], p=0·017) and major adverse cardiovascular events (172 [8·3%] vs 214 [10·3%];
HR 0·80 [0·65–0·97], p=0·026) were less frequent in the CCTA group. Rates of coronary revascularisation procedures
were similar (315 [15·2%] vs 318 [15·3%]; HR 1·00 [0·86–1·17], p=0·99) but preventive therapy prescribing remained
more frequent in the CCTA group (831 [55·9%] of 1486 vs 728 [49·0%] of 1485 patients with available data; odds ratio
1·17 [95% CI 1·01–1·36], p=0·034).
Interpretation After 10 years, CCTA-guided management of patients with stable chest pain was associated with a
sustained reduction in coronary heart disease death or non-fatal myocardial infarction. Identification of coronary
atherosclerosis by CCTA improves long-term cardiovascular disease prevention in patients with stable chest pain.